The results showed that the mRNA expression of Ezrin was significantly increased in the prostate cancer-lymph node metastasis (PCa-L) and the prostate cancer-bone metastasis (PCa-B) groups compared with the prostate cancer group (Figure 1(a)). The gene discussed is EZR; the disease is prostate carcinoma.